For instance, while recombinant IL-33 treatment reduces tumor burden in pancreatic ductal adenocarcinoma, in BCa, IL-33 may exacerbate the ILC2-mediated recruitment and polarization of MDSCs. Here, IL33 is linked to pancreatic ductal adenocarcinoma.